explore -WSS

explore

author：entertainment 2025-09-27 19:49:39 - browse：991

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Medicare slashes safety net hospital payments by nearly $1 billion

focus

WSS

The cancer stories no one wants to hear

Personalized medicine goes far beyond genetics

Personalized medicine goes far beyond genetics

FDA approves Moderna’s RSV vaccine, its second licensed product

FDA approves Sage Therapeutics’ rapid

Biotech startup Celsius cuts 75% of staff ahead of first trial start

leisure time

explore

explore

ChatGPT in medicine: STAT answers readers' burning questions

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Heart attack and stroke risk calculators need revising

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Wildfire smoke exposes gaps in outdoor worker protections

FDA approves Moderna’s RSV vaccine, its second licensed product

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Heart disease in astronauts blamed on cosmic radiation

Anesthesiologist group: stop taking Ozempic before surgery

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

focus

Illumina board agrees to spin off Grail, as divestment plans proceed

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

FDA scientists endorse Pfizer/BioNTech Covid

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Stopping antidepressants leads to symptoms for 1 in 6 patients

Flint parents haunted by uncertainty, fears of lead poisoning

focus

focus

focus

explore